本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Cyclacel Pharmaceuticals

6.37
0.0000
成交量:- -
成交额:145.77万
市值:1,425.11万
市盈率:-0.66
高:6.37
开:6.37
低:6.37
收:6.37
52周最高:597.60
52周最低:3.08
股本:223.90万
流通股本:96.66万
量比:- -
换手率:- -
股息:0.00
股息率:0.02%
每股收益(TTM):-9.6620
每股收益(LYR):-502.4648
净资产收益率:-276.80%
总资产收益率:-102.83%
市净率:3.93
市盈率(LYR):-0.01

数据加载中...

2025/09/12

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2025/09/12

重要事件披露

Form 8-K - Current report
2025/09/05

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2025/09/05

重要事件披露

Form 8-K - Current report
2025/09/04

重要事件披露

Form 8-K - Current report
2025/09/02

重要事件披露

Form 8-K - Current report
2025/08/28

重要事件披露

Form 8-K - Current report
2025/08/25

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2025/08/14

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/08/13

重要事件披露

Form 8-K - Current report
2025/08/13

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2025/08/13

重要事件披露

Form 8-K - Current report
2025/07/31

[修订]招股说明书

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2025/07/28

重要事件披露

Form 8-K - Current report
2025/07/24

SEC问询函

Form CORRESP - Correspondence
2025/07/24

招股说明书

Form S-1 - General form for registration of securities under the Securities Act of 1933
2025/07/24

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/16

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2025/07/16

重要事件披露

Form 8-K - Current report
2025/07/07

企业合并公告

Form 425 - Prospectuses and communications, business combinations